At VarmX, we're transforming the treatment of inherited and acquired coagulation factor disorders that cause bleeding or thrombosis. As COO at VarmX, I’m harnessing my 25+ years of expertise in clinical development, strategy, commercialization, and global business development to bring VarmX to the next growth phase. We're gearing up for a Series C funding round and a Phase 3 clinical trial in urgent hospital care, and I’m thrilled to help lead the charge in this pivotal phase of our journey.

Merging strategic counsel, planning and execution to empower startup biotech and pharma companies in their clinical, commercialisation and business developmentProjects:1. VarmX – SVP Global Commercial Strategy & Business Development (Sept '23 - June '24)2. TargEd - Business Development Advisor (Jan '24-ongoing)3. SynOx – Commercialisation Strategy Advisor (Oct '23 - June '24)4. AM Pharma - Business Development Advisor (Sept '23 - ongoing)

- Lead commercial strategy development for global commercial launch of ilofotase alfa in sepsis associated acute kidney injury (SA-AKI)- Developed full organizational structure and all activities across medical, market access, commercial and supporting functions for pending global launch- Provided commercial leadership for ilofotase alfa’s life cycle strategy- Provided commercial input for and participated on BD Team interacting with (potential) investors and potential strategic partners- First commercial hire for; reporting to CEO; <30 pax, VC investment backed, biotech start-up- Core member BD Team formed to identify path forward for AM-Pharma after phase 3 trial failure, resulting in EUR8Mln funding round for phase 2 trial- Lead BD projects to identify biotech (reverse)merger/acquisition opportunities incl. target identification, engagement, DD, deal structure and generating supporting business cases- Identified and, often thru existing network, engaged with potential pharma or biotech partners/acquirers including development and delivery of tailored AM-Pharma pitch decks

- Build and lead cross-functional Ondexxya (andexanet alfa) Team in the Benelux, Nordics and Alpine from scratch to 15+- Lead P&L, pre-launch, commercialisation, medical, market access & pricing activities across the Region- Core Member of Portola European Leadership Team (Critical Care International Leadership Team post Alexion acquisition)- Director on Portola B.V. Board

- Drive global business development for key target clients, i.e. top 20 pharma- & biotech- Build and maintain relationships with key external clients range from CEOs; global and regional leadership; brand-, medical- and market access-leads- Lead cross-functional internal STEM Team including country General Managers, Regional Heads, local Project Directors and Data Analysts